Anastrozole

Generic Name: Anastrozole

Brand Names: Arimidex

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₉N_₅

CAS Number: 120511-73-1

Unique Ingredient Identifier: 2Z07MYW1AZ

Background: Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...

Indication: Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...

Associated Conditions: Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer

Associated Therapies: -

Clinical Trials

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

Phase 2

Conditions: Breast Cancer

First Posted Date: 2006-11-10

Last Posted Date: 2010-11-09

Lead Sponsor: Technical University of Munich

Target Recruit Count: 94

Registration Number: NCT00398489

Locations: 🇩🇪
Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich, Germany
🇩🇪
Klinikum Deggendorf, Deggendorf, Germany
🇩🇪
Universitaetsfrauenklinik - Koeln, Cologne, Germany

and more 2 locations

Testosterone Effects on Men With the Metabolic Syndrome

Phase 2

Withdrawn

Conditions: Metabolic Syndrome

First Posted Date: 2006-09-28

Last Posted Date: 2008-12-05

Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Target Recruit Count: 72

Registration Number: NCT00382057

Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Anastrozole
Drug: Fulvestrant

First Posted Date: 2006-07-27

Last Posted Date: 2010-12-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 13

Registration Number: NCT00357110

Locations: 🇳🇴
Research SIte, Porsgrunn, Norway
🇳🇴
Research Site, Trondheim, Norway

Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: anastrozole
Drug: simvastatin
Other: pharmacological study
Procedure: adjuvant therapy

First Posted Date: 2006-07-20

Last Posted Date: 2013-06-24

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 11

Registration Number: NCT00354640

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Faslodex Advanced Breast Cancer Local Chinese Study

Phase 3

Completed

Conditions: Advanced Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Anastrozole

First Posted Date: 2006-05-19

Last Posted Date: 2011-01-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 234

Registration Number: NCT00327769

Locations: 🇨🇳
Research Site, Xi AN, China

Arthralgia During Anastrozole Therapy for Breast Cancer

Phase 4

Completed

Conditions: Early Breast Cancer

First Posted Date: 2006-05-09

Last Posted Date: 2012-04-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 114

Registration Number: NCT00323479

Locations: 🇫🇷
Research Site, Poitiers, France

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Phase 3

Active, not recruiting

Conditions: Breast Adenocarcinoma
Stage IA Breast Cancer AJCC v7
Stage IB Breast Cancer AJCC v7
Stage IIA Breast Cancer AJCC v6 and v7
Stage IIB Breast Cancer AJCC v6 and v7
Stage IIIB Breast Cancer AJCC v7
Hormone Receptor Positive

Interventions: Drug: Anastrozole
Drug: Exemestane
Other: Laboratory Biomarker Analysis
Drug: Letrozole
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
Drug: Tamoxifen Citrate

First Posted Date: 2006-04-03

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10273

Registration Number: NCT00310180

Locations: 🇺🇸
Saint Ann's Hospital, Westerville, Ohio, United States
🇨🇦
McGill University Department of Oncology, Montreal, Quebec, Canada
🇨🇦
CHUM-Hotel Dieu de Montreal, Montreal, Quebec, Canada

and more 1212 locations

Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Anastrozole

First Posted Date: 2006-03-13

Last Posted Date: 2023-02-21

Lead Sponsor: Maastricht University Medical Center

Target Recruit Count: 1914

Registration Number: NCT00301457

Locations: 🇳🇱
Research Site, Zwolle, Netherlands

3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Neoplasms

First Posted Date: 2006-03-09

Last Posted Date: 2009-05-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 856

Registration Number: NCT00300508

Locations: 🇦🇹
Research site, Hollabrunn, Austria
🇦🇹
Research Site, Zams, Austria

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: anastrozole
Drug: tamoxifen
Other: goserelin
Drug: zoledronic acid

First Posted Date: 2006-02-24

Last Posted Date: 2024-03-15

Lead Sponsor: Austrian Breast & Colorectal Cancer Study Group

Target Recruit Count: 1803

Registration Number: NCT00295646

Locations: 🇦🇹
State Hospital Klagenfurt, Surgery, Klagenfurt, Carinthia, Austria
🇦🇹
State Hospital Klagenfurt, Klagenfurt, Carinthia, Austria
🇩🇪
Medical University Kiel, Kiel, Schleswig-Holstein, Germany

and more 69 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy